New CAR-T therapy shows promise for tough leukemia in Real-World study
NCT ID NCT07637929
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 200 Chinese patients with relapsed or refractory B-cell acute lymphoblastic leukemia who receive a CAR-T cell therapy called puzolcabtagene autoleucel. The goal is to see how well it works in everyday medical practice, measuring response rates and how long benefits last. The therapy uses a patient's own immune cells, modified to target and kill cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Puzolcabtagene autoleucel (a CAR-T cell therapy made from the patient's own immune cells)
- What this could lead to
- If successful, this could provide a treatment option for patients with hard-to-treat B-cell acute lymphoblastic leukemia, potentially leading to remission.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. CAR-T therapies can cause serious side effects like cytokine release syndrome. The study is early-stage and focused on real-world data, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2032
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients diagnosed with CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), regardless of gender.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with r/r B-ALL who receive treatment with Pucicelant Injection at a research center commercially certified by Chongqing Precision Biotech in China, and whose bone marrow tumor cells are confirmed to express CD19 by flow cytometry * Patients with essentially normal function of vital organs * Patients who voluntarily participate in this study and sign the informed consent form. For patients under 18 years of age, informed consent must also be obtained from their legal guardians Exclusion Criteria: * Patients who test positive for hepatitis C virus (HCV), human immunodeficiency virus (HIV), and Treponema pallidum (TP).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.